{"id":"NCT02252172","sponsor":"Janssen Research & Development, LLC","briefTitle":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","officialTitle":"A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-16","primaryCompletion":"2018-09-24","completion":"2024-10-02","firstPosted":"2014-09-30","resultsPosted":"2020-01-09","lastUpdate":"2025-06-06"},"enrollment":737,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Daratumumab IV","otherNames":["JNJ-54767414"]},{"type":"DRUG","name":"Lenalidomide","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]},{"type":"DRUG","name":"Daratumumab SC","otherNames":["JNJ-54767414"]}],"arms":[{"label":"Lenalidomide and Dexamethasone (Rd)","type":"ACTIVE_COMPARATOR"},{"label":"Daratumumab + Lenalidomide + Dexamethasone (DRd)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).","primaryOutcome":{"measure":"Primary: Progression-free Survival (PFS)","timeFrame":"From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)","effectByArm":[{"arm":"Lenalidomide + Dexamethasone (Rd)","deltaMin":31.87,"sd":null},{"arm":"Daratumumab + Lenalidomide + Dexamethasone (DRd)","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":206,"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Ireland","Israel","Netherlands","Sweden","United Kingdom"]},"refs":{"pmids":["39952901","39815052","39229471","37212642","36067063","34655533","34289038","34269818","33326255","31141632"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":229,"n":365},"commonTop":["Diarrhoea","Neutropenia","Constipation","Anaemia","Fatigue"]}}